Clinical Trial: Use of 852A in Metastatic Cutaneous Melanoma.
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Pilot Phase II, Open Label, Multicenter, Efficacy and Safety Study of 852A Administered Intravenously to Subjects With Unresectable Metastatic Cutaneous Melanoma.
Brief Summary: Pilot study to test the efficacy of 852A administered intravenously up to 3 times per week for 12 weeks in subjects with inoperable metastatic cutaneous melanoma.
Detailed Summary:
Sponsor: Pfizer
Current Primary Outcome: assessing antitumor activity of 852A intravenous bolus injection administered 3 times a week for 12 weeks
Original Primary Outcome: - assessing antitumor activity of 852A intravenous bolus injection administered 3 times a week for 12 weeks
Current Secondary Outcome:
- to assess the safety of the dosage regiment over 12 weeks
- to obtain preliminary data regarding the safety and long term efficacy of 852A in subjects treated with the drug for more than 12 weeks
Original Secondary Outcome: Same as current
Information By: Pfizer
Dates:
Date Received: September 13, 2005
Date Started: February 2005
Date Completion:
Last Updated: October 24, 2008
Last Verified: October 2008
